Filing Flows › Niagen Bioscience (NAGE) › Q2 2026 › vs Q1 2026
Niagen Bioscience (NAGE) Q2 2026 vs Q1 2026 (quarter over quarter)
Niagen Bioscience's revenue fell $1.7M (-5%) from $31.5M in Q1 2026 to $29.8M in Q2 2026. The biggest changes: Ingredients segment −$3.2M (-37%); Consumer Products segment +$1.7M (+8%); Corporate and other +$162K (+219%). Gross margin 64.8% against 63.5% (+1.4 pts).
Niagen Bioscience, Q2 2026: revenue $29.8M (-4% year over year), operating margin 2.4%, net earnings $963K, operating cash flow $2.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 64.8% | 63.5% | +1.4 pts |
| Operating margin | 2.4% | 5.0% | -2.7 pts |
| Net margin | 3.2% | 20.1% | -16.8 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Consumer Products segment | $24.2M | $22.4M | $1.7M | +8% |
| Ingredients segment | $5.4M | $8.6M | −$3.2M | -37% |
| Corporate and other | $236K | $74K | $162K | +219% |
| Revenue | $29.8M | $31.5M | −$1.7M | -5% |
| Gross profit | $19.3M | $20.0M | −$662K | -3% |
| Cost of revenue | $10.5M | $11.5M | −$1.0M | -9% |
| Other income, net | $369K | $5.2M | −$4.8M | -93% |
| Operating profit | $700K | $1.6M | −$876K | -56% |
| Operating expenses | $18.6M | $18.4M | $214K | +1% |
| Pre-tax earnings | $1.1M | $6.7M | −$5.7M | -84% |
| Research & development | $1.5M | $1.5M | $32K | +2% |
| Sales & marketing | $10.1M | $9.7M | $455K | +5% |
| General & admin | $7.0M | $7.2M | −$273K | -4% |
| Net earnings | $963K | $6.3M | −$5.4M | -85% |
| Income tax | $106K | $417K | −$311K | -75% |
| Depreciation & amortization | $291K | $291K | $0 | 0% |
| Share-based compensation | $1.7M | $1.7M | $7K | +0.4% |
| Working capital & other | $205K | $9.5M | −$9.3M | -98% |
| Operating cash flow | $2.8M | −$1.2M | $4.0M | — |
Questions
How much did Niagen Bioscience's revenue grow quarter over quarter in Q2 2026?
Niagen Bioscience's revenue fell $1.7M (-5%) from $31.5M in Q1 2026 to $29.8M in Q2 2026.
What drove Niagen Bioscience's revenue change in Q2 2026?
Ingredients segment −$3.2M (-37%); Consumer Products segment +$1.7M (+8%); Corporate and other +$162K (+219%).